Current systematic reviews on the utilization of triamcinolone acetonide for treating macular edema have largely been confined to meta-analyses, predominantly comparing it either to placebo alone or to anti-VEGF treatments [61–63]. This evidence concerns the gene VEGFA and macular retinal edema.